Cargando…

Effectiveness of Three Prognostic Scoring Systems in Predicting the Response and Outcome in Pediatric Chronic Myeloid Leukemia Chronic Phase on Frontline Imatinib

INTRODUCTION: The Sokal and Hasford (Euro) scores were developed in the chemotherapy and interferon eras and are widely used as prognostic indicators in patients with chronic myeloid leukemia (CML). Recently, European Treatment and Outcome Study (EUTOS) scoring system was introduced. Data on risk st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ganta, Ranga Raman, Nasaka, Srividya, Linga, Vijay Gandhi, Gundeti, Sadashivudu, Maddali, Lakshmi Srinivas, Digumarti, Raghunadha Rao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686967/ https://www.ncbi.nlm.nih.gov/pubmed/29200674 http://dx.doi.org/10.4103/ijmpo.ijmpo_104_16

Ejemplares similares

Impact of treatment protocol on outcome of localized Ewing's sarcoma
por: Nasaka, Srividya, et al.
Publicado: (2016)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Trends in management of acute lymphoblastic leukemia: Influence of insurance based healthcare and treatment compliance on the outcome of adolescents and adults with acute lymphoblastic leukemia
por: Arigela, Ravi Sankar, et al.
Publicado: (2016)

Clinicopathological features and outcomes in advanced nonsmall cell lung cancer with tailored therapy
por: Bala, Stalin, et al.
Publicado: (2016)

Managing metastatic renal cell carcinoma-challenges, pitfalls, and outcomes in the real world
por: Kumar, Karnam Ashok, et al.
Publicado: (2016)

Prevalence and outcome of epidermal growth factor receptor mutations in non-squamous non-small cell lung cancer patients
por: Kota, Rajesh, et al.
Publicado: (2015)

The Role of Mutation Testing in Patients with Chronic Myeloid Leukemia in Chronic Phase after Imatinib Failure and Their Outcomes after Treatment Modification: Single-institutional Experience Over 13 Years
por: Chaitanya, Puligundla Krishna, et al.
Publicado: (2017)

Epedimiologic, clinical profile and factors affecting the outcome in febrile neutropenia
por: Krishnamani, Kalpathi, et al.
Publicado: (2017)

Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate
por: Rajappa, Senthil, et al.
Publicado: (2013)

Primary pleuropulmonary synovial sarcoma: A report of two cases and review of literature
por: Kalpathi, Krishnamani, et al.
Publicado: (2013)

Parasagittal hemangiopericytoma with late presentation of liver metastases: Case report and review of literature
por: Krishnamani, Kalpathi V., et al.
Publicado: (2013)

Association of The Common CYP1A1*2C Variant (Ile462Val Polymorphism) with Chronic Myeloid Leukemia (CML) in Patients Undergoing Imatinib Therapy
por: Lakkireddy, Samyuktha, et al.
Publicado: (2015)

Renal Lymphoma: Primary or First Manifestation of Aggressive Pediatric B-cell Lymphoma
por: Coca, Pragnya, et al.
Publicado: (2017)

Clinical profile and outcome of adult Hodgkin lymphoma: Experience from a tertiary care institution
por: Maddi, Rahul Narayan, et al.
Publicado: (2015)

Thiopurine methyltransferase polymorphisms in children with acute lymphoblastic leukemia
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Treatment Challenges and Survival Analysis of Human Epidermal Growth Factor Receptor 2-positive Breast Cancer in Real World
por: Adusumilli, Praveen, et al.
Publicado: (2017)

Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China
por: Cheng, Fang, et al.
Publicado: (2023)

Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia
por: Banjar, Haneen, et al.
Publicado: (2017)

Metastatic adenocarcinoma in a young male, 12 years after treatment of primary non seminomatous germ cell tumor
por: Coca, Pragnya, et al.
Publicado: (2011)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
por: Chandra, Abhilash, et al.
Publicado: (2020)

Philadelphia chromosome-positive acute lymphoblastic leukemia: 8 years’ experience from a tertiary care center in India
por: Danthala, Madhav, et al.
Publicado: (2016)

Chronic myeloid leukemia: An Indian scenario
por: Digumarti, Raghunadharao
Publicado: (2016)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Clinicopathological Features and Outcomes in Primary Central Nervous System Lymphoma: A 10-year Experience
por: Puligundla, Chaitanya Krishna, et al.
Publicado: (2017)

Impact of cytogenetics on outcomes in pediatric acute lymphoblastic leukemia
por: Chennamaneni, Rachana, et al.
Publicado: (2018)

Outcome of Frontline Treatment with “Generic” Imatinib In Adult Patients with Chronic Myeloid Leukemia in Algerian Population: A Multicenter Study
por: Entasoltan, B., et al.
Publicado: (2017)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
por: Kantarjian, Hagop M., et al.
Publicado: (2021)

Debating Frontline Therapy in Chronic Myeloid Leukemia
por: Bi, Xia, et al.
Publicado: (2021)

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
por: Hochhaus, A, et al.
Publicado: (2016)

RAPID CONVERSION OF CHRONIC MYELOID LEUKEMIA TO CHRONIC MYELOMONOCYTIC LEUKEMIA IN A PATIENT ON IMATINIB THERAPY
por: Khorashad, Jamshid S., et al.
Publicado: (2016)

Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia
por: Kim, Kibum, et al.
Publicado: (2019)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Imatinib-Induced Tremor in a Patient with Chronic Myeloid Leukemia in Chronic Phase
por: Obeidat, Khaldun, et al.
Publicado: (2019)

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
por: Kavanagh, Simon, et al.
Publicado: (2018)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia
por: DeRemer, David L, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_gpd3c74up9fg2inq2kh1b9fu6k